HPVE6/E7mRNA在宫颈病变中的应用价值被引量：9

导出

摘要目的对宫颈病变患者宫颈HPVE6/E7mRNA的表达情况进行检测,探讨HPVE6/E7mRNA在宫颈病变诊断中的应用价值。方法选择2014年12月-2016年4月在金华市浦江县妇幼保健院宫颈门诊进行宫颈液基细胞血检查及宫颈病理学检查的500例患者作为研究对象,其中病理检查结果显示宫颈正常或者宫颈慢性炎症者314例,宫颈上皮内瘤变(CIN)Ⅰ级者78例,CINⅡ级39例,CINⅢ级者33例,宫颈癌16例。观察宫颈不同病变组患者中HPV DNA和HPVE6/E7mRNA的检测情况、宫颈HPV DNA检测结果及HPVE6/E7mRNA检测结果和宫颈病理结果的比较情况、HPV DNA和HPVE6/E7mRNA对宫颈癌及宫颈CIN的筛查结果比较情况。结果宫颈不同病变组患者HPV DNA阳性率比较,差异有统计学意义(P<0.05)。宫颈HPV DNA检测结果和宫颈病理结果比较,差异有统计学意义(P<0.05)。宫颈不同病变组患者HPVE6/E7mRNA阳性率比较,差异有统计学意义(P<0.05)。宫颈HPVE6/E7mRNA检测结果和宫颈病理结果比较,差异有统计学意义(P<0.05)。HPVE6/E7mRNA对宫颈癌和宫颈CIN的筛查特异度和阳性预测值均高于HPV DNA(P<0.05)。结论 HPVE6/E7mRNA对宫颈疾病的预测灵敏度和HPV DNA相似,但HPVE6/E7mRNA的预测特异度高于HPV DNA,在宫颈病变的筛查中具有一定意义,可以作为宫颈病变的筛查方法。

作者黄美环朱燕飞

机构地区金华市浦江县妇幼保健院妇产科永康市妇幼保健院产科

出处《中国妇幼保健》 CAS 2016年第16期3381-3383,共3页 Maternal and Child Health Care of China

基金浙江省医药卫生一般研究计划项目(2014KYB301) 2015年浦江县科学技术研究计划项目(15W16)

关键词 HPVE6/E7mRNA 宫颈病变宫颈癌

分类号 R711.74 [医药卫生—妇产科学]

引文网络
相关文献

参考文献15

1刘桐宇,谢榕,Lulu Zhang,郑雄伟,陈刚,何诚,林玉珍,杨琳,李桑.TCT标本检测高危HPV E6/E7mRNA及在宫颈病变中的应用研究[J].中华妇幼临床医学杂志（电子版）,2011,7(3):166-169. 被引量：35
2周星,刘丽华,张金库,赵文明,姜丽,陈红,周炳娟.宫颈脱落细胞HPV E6/E7 mRNA、HR-HPV DNA在宫颈病变筛查中的应用[J].山东医药,2014,54(6):54-56. 被引量：18
3Siriaunkgul S, Settakorn J, Sukpan K, et al. Population-based cervi- cal cancer screening using high- risk HPV DNA test and liquid- basedcytology in northern Thailand [ J 1. Asian Pac J Cancer Prev, 2014, 15 (16) : 6837-6842.
4Ali KS, Ali HY, Jubrael JM. Concentration levels of IL- 10 and TNFa cytokines in patients with human papilloma virus (HPV) DNA+ and DNA- cervical lesions [J].J Immunotoxicol, 2012, 9 (2) : 168-172.
5Igidbashian S, Schettino MT, Boveri S, et al. Tissue genotyping of 37 in situ and invasive cervical cancer with a concomitant negative HC2 HPVDNA test [ J ]. J Low Genit Tract Dis, 2014, 18 (1): 87-91.
6Munkhdelger J, Kim G, Wang HY, et al. Performance of HPV E6/E7 mRNA RT-qPCR for screening and diagnosis of cervical cancer with Thin Prep Pap test samples [J]. Exp Mol Pathol, 2014, 97 (2) : 279 -284.
7Galarowicz B, Jach R, Kidzierska J, et al. The role of mRNA E6/E7 HPV high oncogenic risk expression in colposcopy of cervicalintraepi- thelial neoplasia ( CIN ) [J]. Przegl Lek, 2012, 69 (9) : 651-657.
8Karimi-Zarchi M, Peighmbari F, Karimi N, et al. A comparison of 3 ways of conventional pap smear, liquid-based cytology and colposcopy vs cervical biopsy for early diagnosis of premalignant lesions or cervical cancer in women with abnormal conventional pap test [J]. Int J Bi- omed Sci, 2013, 9 (4): 205-210.
9Pan Q J, Hu SY, Zhang X, et al. Pooled analysis of the performance ofliquid-based cytology in population-based cervical cancer screening studies in China [ J ]. Cancer Cytopathol, 2013, 121 ( 9 ) : 473 -482.
10Krajowa Izba Diagnostow Laboratoryjnych, Polskie Towarzystwo Ginekologiczne. Guidelines for application of molecular tests identyfying HR HPV DNA in the prevention ofcervical cancer. Statement of experts from PGS (PTG) and NCLD (KIDL) [J]. Ginekol Pol, 2013, 84 (5): 395-399.

二级参考文献28

1Mu(n)oz N,Castellsagué X,de González AB,et al.Chapter 1:HPV in the etiology of human cancer[J].Vaccine,2006,24(Suppl 3):S3/1-10.
2Brink AA,Snijders PJ,Meijer CJ,et al.HPV testing in cervical screening[J].Best Praet Res Clin Obstet Gynaecol,2006,20(2):253-266.
3Lie AK,Kristensen G.Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical cancinoma[J].Expert Rev Mol Diagn,2008,8(4):405-415.
4Castle PE,Dockter J,Giachetti C,et al.A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical preeancer and cancer[J].Clin Cancer Res,2007,13(9):2599-2605.
5Andersson S,Hansson B,Norman I,et al.Expression of E6/E7 mRNA from 'high risk' human papillomavirus in relation to CIN grade,viral load and p161NK4a[J].Int J Oncol,2006,29(3):705-711.
6Molden T,Nygard JF,Kraus I,et al.Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR:A 2-year follow-up of women with ASCUS or LSIL Pap smear[J].Int J Cancer,2005,114(6):973-976.
7Saeterdal IM,Juvet LK,Norderhaug IN.HPV RNA test for cervical cancer[R].Rapport fra Kunnskapssenteret,NOKC nr 02-2008.
8Cuschieri K,Wentzensen N.Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia[J].Cancer Epidemiol Biomarkers Prey,2008,17(10):2536-2545.
9Bianchi A,Moret F,Desrues JM,et al.PreservCyt transport medium used for the ThinPrep Pap test is a suitable medium for detection of Chlamydia trachomatis by the COBAS Amplicor CT/NG test:Results of a preliminary study and future implications[J].J Clin Microbiol,2002,40(5):1749-1754.
10Cattani P,Zannoni GF,Ricci C,et al.Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix[J].J Clin Microbiol,2009,47(12):3895-3901.